Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
DOI:
https://doi.org/10.37762/jgmds.9-1.173Keywords:
Type 2 diabetes mellitus, Glycated Heamoglobin, EmpagliflozinAbstract
OBJECTIVES:
To assess efficacy of two doses i.e., 10 mg and 25 mg in lowering the glycated haemoglobin (HbA1C) and fasting blood glucose (FBG) in patients of type 2 diabetes mellitus (T2DM) having suboptimal glycaemic control on maximal doses of Metformin and Sitagliptin, and to see the frequency of its side-effects.
METHODOLOGY:
The study design was a randomized control trial. Fifty nine adult patients of T2DM who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C >7% and <12%) were randomized to two groups, one group receiving 10 mg (Group A) and the other group receiving 25 mg of empagliflozin (Group B) as an additional treatment. HbA1C and FBG were taken before and 12 weeks after addition of empagliflozin in both the groups. Side effects of empagliflozin such as urinary tract infections (UTI) and genital mycotic infections were also recorded in both the groups.
RESULTS:
Total patients in-group A were 31 and their mean age was 51.48±4.29 years. In-group B there were 28 patients and their mean age was 52.39±5.20 years. There was a statistically significant reduction of both HbA1C and FBG in both the groups after empagliflozin treatment; (p=0.000) for both HbA1C and FBG in both the groups. Although numerically UTI and genital mycotic infections were more than pre-treatment numbers, they were not statistically significant (p>0.05).
CONCLUSION:
Empagliflozin can be safely added to the oral anti-diabetic regimen of patients with type 2 diabetes mellitus who have suboptimal glycaemic control and results in significant improvement in HbA1C.
Downloads
Metrics
References
Cherukuri L, Smith MS, Tayek JA. The durability of oral diabetic medications: time to A1c baseline and a review of common oral medications used by the primary care provider. Endocrinol Diabetes Metab J. 2018;2(3) DOI: https://doi.org/10.31038/EDMJ.2018232
Chen RC, Jiang HQ, Huang CY, Bau CT. Clinical decision support system for diabetes based on ontology reasoning and TOPSIS analysis. J Healthcare Eng. 2017;2017 DOI: https://doi.org/10.1155/2017/4307508
Aucott LS, Philip S, Avenell A, Afolabi E, Sattar N, Wild S. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open. 2016;6(7):e010836 DOI: https://doi.org/10.1136/bmjopen-2015-010836
Mkrtumyan AM, Markova TN, Mishchenko NK. The role of the kidneys in glucose homeostasis. Probl Endocrinol. 2017;63(6):385-91. DOI: https://doi.org/10.14341/probl2017636385-391
Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic tar¬get for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12:78-89 DOI: https://doi.org/10.1177/1479164114561992
Hong AR, Koo BK, Kim SW, Yi KH, Moon MK. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in Korean patients with type 2 diabetes mellitus in real-world clinical practice. Diabetes Metab J. 2019;43(5):590-606 DOI: https://doi.org/10.4093/dmj.2018.0134
Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37(8):1773-88 DOI: https://doi.org/10.1016/j.clinthera.2015.05.511
Toto RD, Goldenberg R, Chertow GM, Cain V, Stefánsson BV, Sjöström CD, et al. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications. 2019;33(10):107402 DOI: https://doi.org/10.1016/j.jdiacomp.2019.06.007
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9 DOI: https://doi.org/10.2337/dc14-2441
Kumar S, Khatik GL, Mittal A. Recent developments in sodium-glucose co-transporter 2 (SGLT2) inhibitors as a valuable tool in the treatment of type 2 diabetes mellitus. Mini Rev Med Chem. 2020;20(3):170-82 DOI: https://doi.org/10.2174/1389557519666191009163519
Softeland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40(2):201-9 DOI: https://doi.org/10.2337/dc16-1347
Zhong X, Lai D, Ye Y, Yang X, Yu B, Huang Y. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016;72(6):655-63 DOI: https://doi.org/10.1007/s00228-016-2010-8
Zhang YJ, Han SL, Sun XF, Wang SX, Wang HY, Liu X, et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Medicine. 2018;97(43) DOI: https://doi.org/10.1097/MD.0000000000012843
Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394-402 DOI: https://doi.org/10.2337/dc14-2365
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, WoerleHJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936-48 DOI: https://doi.org/10.1111/dom.12503
Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17(7):699-702 DOI: https://doi.org/10.1111/dom.12469
Sohail E, Ahsan T, Ghaus S, Aijaz W. SGLT 2 inhibitors; glycemic control, weight loss and safety profile in patients with type 2 diabetes at Medicell Institute (MIDEM). Pak J Med Sci. 2021;37(1):87-92 DOI: https://doi.org/10.12669/pjms.37.1.2701
Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Dia¬betes Obes Metab. 2013;15(8):721-8 DOI: https://doi.org/10.1111/dom.12081
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Nauman Wazir, Shafqat Ur Rehman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
